Chronic administration of a norepinephrine antagonist prevents and partially reverses escalation of cocaine self‐administration
Authors:
Open Access
- 16 August 2023
- journal article
- research article
- Published by Wiley in Addiction Biology
- Vol. 28 (9) , e13316
Abstract
Anxiety is a critical component of the development and maintenance of drug addiction; however, anti‐anxiety medications such as benzodiazepines and beta‐blockers (β‐adrenergic receptor antagonists) are not used for the treatment of substance use disorder, except for the management of acute withdrawal syndrome. Preclinical studies have shown that beta‐blockers may reduce stress‐induced relapse; however, the effect of beta blockers on the escalation and maintenance of drug intake has not been tested. To address this issue, we chronically administered the β‐adrenergic receptor antagonist propranolol during the escalation or maintenance of cocaine intake in a model of extended access (6 h) to cocaine self‐administration (0.5 mg/kg). The behavioural specificity of propranolol was tested using a non‐drug reward (saccharin). Daily administration of propranolol (15 mg/kg) prevented the development of escalation of cocaine self‐administration and partially reversed self‐administration after the establishment of escalation of intake. Moreover, propranolol dose‐dependently decreased the motivation for cocaine tested under a progressive ratio schedule of reinforcement during the development of escalation and after maintenance. Finally, propranolol administration had no effect on the escalation and maintenance of saccharin self‐administration. These results demonstrate that chronic treatment with propranolol provides therapeutic efficacy in reducing cocaine self‐administration during the development and after the establishment of escalation of cocaine self‐administration in an animal model relevant to cocaine use disorder. These results suggest that beta blockers should be further investigated as a target for medication development for the treatment of cocaine use disorder.Keywords
Funding Information
- National Institutes of Health (U01DA043799)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (019‐163LW.011)
This publication has 28 references indexed in Scilit:
- Substance Use Disorders and Anxiety: A Treatment Challenge for Social WorkersSocial Work in Public Health, 2013
- Elevated Norepinephrine may be a Unifying Etiological Factor in the Abuse of a Broad Range of Substances: Alcohol, Nicotine, Marijuana, Heroin, Cocaine, and CaffeineSubstance Abuse: Research and Treatment, 2013
- The effect of propranolol dose and novelty of the reactivation procedure on the reconsolidation of a morphine place preferenceBehavioural Brain Research, 2011
- Pharmacodynamic and Pharmacokinetic Interactions of Propranolol with Garlic (Allium sativum) in RatsEvidence-Based Complementary and Alternative Medicine, 2011
- Individual differences in prefrontal cortex function and the transition from drug use to drug dependenceNeuroscience & Biobehavioral Reviews, 2010
- Disulfiram Attenuates Drug-Primed Reinstatement of Cocaine Seeking via Inhibition of Dopamine β-HydroxylaseNeuropsychopharmacology, 2010
- A Role for Brain Stress Systems in AddictionNeuron, 2008
- α1-Noradrenergic system role in increased motivation for cocaine intake in rats with prolonged accessEuropean Neuropsychopharmacology, 2008
- Stress, Dysregulation of Drug Reward Pathways, and the Transition to Drug DependenceAmerican Journal of Psychiatry, 2007
- Progressive Ratio as a Measure of Reward StrengthScience, 1961